Research Analysts Issue Forecasts for RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Cartesian Therapeutics in a report issued on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($3.65) per share for the year. Cantor Fitzgerald has a “Hold” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright cut their price objective on shares of Cartesian Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, March 14th. BTIG Research began coverage on shares of Cartesian Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $42.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Cartesian Therapeutics in a research note on Thursday, March 13th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.14.

Cartesian Therapeutics Stock Performance

Shares of Cartesian Therapeutics stock opened at $15.93 on Wednesday. Cartesian Therapeutics has a 52-week low of $11.67 and a 52-week high of $41.87. The stock has a market capitalization of $412.70 million, a price-to-earnings ratio of -0.30 and a beta of 0.71. The company has a fifty day moving average of $18.41 and a 200-day moving average of $18.72.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in Cartesian Therapeutics by 458.3% in the 3rd quarter. FMR LLC now owns 2,851,830 shares of the company’s stock worth $45,972,000 after purchasing an additional 2,341,054 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Cartesian Therapeutics by 122.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company’s stock worth $27,000 after purchasing an additional 909 shares in the last quarter. State Street Corp raised its holdings in Cartesian Therapeutics by 2.5% in the 3rd quarter. State Street Corp now owns 157,495 shares of the company’s stock worth $2,539,000 after purchasing an additional 3,830 shares in the last quarter. Great Point Partners LLC bought a new position in Cartesian Therapeutics in the 3rd quarter worth $3,224,000. Finally, Barclays PLC raised its holdings in Cartesian Therapeutics by 208.6% in the 3rd quarter. Barclays PLC now owns 11,611 shares of the company’s stock worth $188,000 after purchasing an additional 7,849 shares in the last quarter. 86.95% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cartesian Therapeutics

In other Cartesian Therapeutics news, CTO Metin Kurtoglu sold 2,458 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $16.83, for a total transaction of $41,368.14. Following the completion of the sale, the chief technology officer now owns 62,258 shares of the company’s stock, valued at $1,047,802.14. This represents a 3.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Blaine Davis sold 3,961 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $16.72, for a total transaction of $66,227.92. Following the sale, the chief financial officer now directly owns 98,839 shares of the company’s stock, valued at $1,652,588.08. The trade was a 3.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,744 shares of company stock valued at $247,337 in the last quarter. Company insiders own 57.90% of the company’s stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.